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Optimal vaccination strategies against HIV-1 require the
fulfilment of two conditions: a)- the choice of an immu-
nogen including pathogen's antigenic epitopes against
which an immune response with neutralizing characteris-
tics can be generated; b) the optimisation of triggering and
maintenance of the immune response against the vaccine.
Our interest is focussed on the second aspect. The expres-
sion of the MHC class-II transactivator (CIITA) whose
locus AIR-1 and corresponding function were discovered
in our laboratory, is needed for continuous expression of
MHC class-II molecules and consequent antigen present-
ing function by APC. Unexpectedly, and of great relevance
for antiviral functions, we found that CIITA potently
inhibits HIV-1 viral replication by a competitive action on
the viral transactivator Tat for Cyclin T1, the cellular cofac-
tor used by Tat to elongate viral transcripts. This effect is
found in APC and, of greater importance, also in HIV-1-
infected T cells. Molecular analysis has revealed that the
inhibitory activity of CIITA for HIV-1 Tat maps to the N-
terminal region, and particularly to the segment 200–285
included within the P/S/T region of the CIITA activation
domain which is then the molecularly defined Cyclin-T1-
interacting region. Thus CIITA has a dual role on HIV
infection: 1)- it increases APC function for HIV-1 viral
antigens; 2)- it decreases viral replication and thus viral
spreading in infected individuals. Within this frame CIITA
represents the necessary and ideal molecule to control
both innate and adaptive immunity against the virus.
Considering the functional importance of a sustained and
persistent expression of CIITA in APC, the search for
potential synthetic and natural mediators, drugs and bio-
molecules, that can act on CIITA expression at level of
transcription as well as biosynthesis, will be of great
importance in tailoring better vaccines against HIV-1, and
in controlling and combating HIV-1 infection and spread-
ing.
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